https://www.selleckchem.com/autophagy.html
0 years) were not likely to respond to exenatide. WHAT IS NEW AND CONCLUSION Our data indicate that T2DM patients with a higher baseline HbA1C and a shorter duration of diabetes are more likely to have a glycaemic response to exenatide than those with a lower baseline HbA1C and a longer duration of diabetes. The identification of predictors of therapeutic response to exenatide can provide clinically useful information for characterizing the patients who could receive the greatest benefit from exenatide. © 2020 John Wiley Sons Ltd.PURPOSE
Gefällt mir
Kommentar
Teilen
